$3.11
+0.04 (+1.30%)
Open$3.07
Previous Close$3.07
Day High$3.23
Day Low$3.06
52W High$5.15
52W Low$2.44
Volume—
Avg Volume571.4K
Market Cap267.50M
P/E Ratio20.15
EPS$-1.42
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+910.0% upside
Current
$3.11
$3.11
Target
$31.41
$31.41
$26.29
$31.41 avg
$48.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 92.27M | 83.15M | 89.97M |
| Net Income | 5.58M | 4.38M | 5.69M |
| Profit Margin | 6.1% | 5.3% | 6.3% |
| EBITDA | 11.07M | 10.58M | 10.22M |
| Free Cash Flow | 5.66M | 4.59M | 4.29M |
| Rev Growth | -8.1% | +18.1% | +3.5% |
| Debt/Equity | 0.85 | 0.76 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |